Neurizon creates liquid formula to improve accessibility of ALS treatment

• NUZ develops oral liquid formula of NUZ-001 ALS treatment
• Company expects to both improve patient experience and drugs commercial potential
• New formula to be included in upcoming human clinical trials

Special Report: Neurizon Therapeutics has developed a new oral liquid formulation of its NUZ-001 drug for the treatment of Amyotrophic Lateral Sclerosis (ALS) in a move expected to improve accessibility and ease administration of the treatment.

The liquid formulation is designed to support patients with all stages of ALS, particularly those with swallowing difficulties – ensuring broader access to therapy.

The key advantages of the liquid formulation include: 

• Improved ease of swallowing for patients with dysphagia or speech impairment
• Flexible dosing across a range of patient weights and tolerances
• Enteral (feeding tube) administration, ensuring continuity of treatment
• Simplified administration for caregivers and clinical teams

It’s part of Neurizon Therapeutics’ (ASX:NUZ) patient-centric innovation strategy, with the goal to enhance the continuation of treatment, ease administration and improve the overall treatment experience for patients.

Plus, it supports the company’s strategy to transform from a single product to a scalable long-term treatment platform to unlock both patient and commercial value.

Planned use in clinical trial

The company is now integrating the new formulation into its ongoing clinical development program for NUZ-001 – with a human bioequivalence study alongside the standard tablet form, scheduled to begin in H1 CY 2026.

“As ALS progresses, patients face increasing challenges with day-to-day activities, including something as fundamental as swallowing,” MD and CEO Dr Michael Thurn said. 

“This innovation is about flexibility, inclusion, and staying aligned with the needs of people living with ALS. 

“Developing a successful oral liquid formulation – especially for a therapeutic like NUZ-001 targeting a vulnerable patient population – requires careful consideration of physical, chemical, and compatibility factors to ensure stability, bioavailability, and patient usability. 

“By offering NUZ-001 in a liquid form, we’re ensuring that more patients can benefit from the therapy throughout all stages of disease progression.”

This article was developed in collaboration with Neurizon Therapeutics, a Stockhead advertiser at the time of publishing. 

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.